先进治疗药物 CDMO 市场 - 全球产业规模、份额、趋势、机会和预测，按产品、阶段、适应症、地区和竞争细分，2020-2030 年预测

2024 年全球先进治疗药物 CDMO 市值为 51.2 亿美元，预计到 2030 年将达到 88.7 亿美元，预测期内复合年增长率为 9.54%。全球先进治疗药物 CDMO 市场是製药和生物技术产业内一个充满活力且快速发展的领域。该市场涵盖为先进治疗药物（ATMP）的开发和製造提供专业服务的组织，其中包括基因疗法、细胞疗法和组织工程产品。

主要市场驱动因素

先进疗法的普及

主要市场挑战

成本高昂

主要市场趋势

加强合作与伙伴关係

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球先进治疗药物 CDMO 市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（基因治疗、细胞治疗、组织工程、其他）
  • 依阶段划分（第一阶段、第二阶段、第三阶段、第四阶段）
  • 按适应症（肿瘤科、心臟科、中枢神经系统科、肌肉骨骼科、传染病科、免疫科及发炎科、其他科）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美先进治疗药物 CDMO 市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲先进治疗药物 CDMO 市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区先进治疗药物 CDMO 市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲先进治疗药物 CDMO 市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲先进治疗药物 CDMO 市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Celonic AG
• Rentschler Biopharma SE
• Catalent, Inc.
• Lonza Group AG
• WuXi Advanced Therapies
• Minaris Regenerative Medicine, LLC
• Pluri Biotech Ltd.
• REPROCELL USA Inc.
• BioPhorum Operations Group
• Cellares Corporation

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during the forecast period. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.

Key Market Drivers

Proliferation of Advanced Therapies

The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).

The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.

Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.

The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.

Key Market Challenges

High Costs

The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process. Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.

Key Market Trends

Increased Collaboration and Partnerships

Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions. These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.

Key Market Players

• Celonic AG
• Rentschler Biopharma SE
• Catalent, Inc.
• Lonza Group AG
• WuXi Advanced Therapies
• Minaris Regenerative Medicine, LLC
• Pluri Biotech Ltd.
• REPROCELL USA Inc.
• BioPhorum Operations Group
• Cellares Corporation

Report Scope:

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product:

• Gene Therapy
• Cell Therapy
• Tissue Engineered
• Others

Advanced Therapy Medicinal Products CDMO Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Advanced Therapy Medicinal Products CDMO Market, By Indication:

• Oncology
• Cardiology
• Central Nervous System
• Musculoskeletal
• Infectious disease
• Immunology & inflammation
• Others

Advanced Therapy Medicinal Products CDMO Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

Global Advanced Therapy Medicinal Products CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Advanced Therapy Medicinal Products CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
  • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Advanced Therapy Medicinal Products CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Phase
  • 6.2.3. By Indication
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Phase
      • 6.3.1.2.3. By Indication
  • 6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Phase
      • 6.3.2.2.3. By Indication
  • 6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Phase
      • 6.3.3.2.3. By Indication

7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Phase
  • 7.2.3. By Indication
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Phase
      • 7.3.1.2.3. By Indication
  • 7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Phase
      • 7.3.2.2.3. By Indication
  • 7.3.3. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Phase
      • 7.3.3.2.3. By Indication
  • 7.3.4. France Advanced Therapy Medicinal Products CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Phase
      • 7.3.4.2.3. By Indication
  • 7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Phase
      • 7.3.5.2.3. By Indication

8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Phase
  • 8.2.3. By Indication
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Phase
      • 8.3.1.2.3. By Indication
  • 8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Phase
      • 8.3.2.2.3. By Indication
  • 8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Phase
      • 8.3.3.2.3. By Indication
  • 8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Phase
      • 8.3.4.2.3. By Indication
  • 8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Phase
      • 8.3.5.2.3. By Indication

9. South America Advanced Therapy Medicinal Products CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Phase
  • 9.2.3. By Indication
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Phase
      • 9.3.1.2.3. By Indication
  • 9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Phase
      • 9.3.2.2.3. By Indication
  • 9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Phase
      • 9.3.3.2.3. By Indication

10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Phase
  • 10.2.3. By Indication
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Phase
      • 10.3.1.2.3. By Indication
  • 10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Phase
      • 10.3.2.2.3. By Indication
  • 10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Phase
      • 10.3.3.2.3. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Celonic AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Rentschler Biopharma SE
• 14.3. Catalent, Inc.
• 14.4. Lonza Group AG
• 14.5. WuXi Advanced Therapies
• 14.6. Minaris Regenerative Medicine, LLC
• 14.7. Pluri Biotech Ltd.
• 14.8. REPROCELL USA Inc.
• 14.9. BioPhorum Operations Group
• 14.10. Cellares Corporation

15. Strategic Recommendations

16. About Us & Disclaimer